1. Home
  2. PFLT vs TNGX Comparison

PFLT vs TNGX Comparison

Compare PFLT & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PFLT
  • TNGX
  • Stock Information
  • Founded
  • PFLT N/A
  • TNGX 2014
  • Country
  • PFLT United States
  • TNGX United States
  • Employees
  • PFLT N/A
  • TNGX N/A
  • Industry
  • PFLT Finance: Consumer Services
  • TNGX Biotechnology: Pharmaceutical Preparations
  • Sector
  • PFLT Finance
  • TNGX Health Care
  • Exchange
  • PFLT Nasdaq
  • TNGX Nasdaq
  • Market Cap
  • PFLT N/A
  • TNGX 990.5M
  • IPO Year
  • PFLT N/A
  • TNGX N/A
  • Fundamental
  • Price
  • PFLT $11.38
  • TNGX $9.89
  • Analyst Decision
  • PFLT Buy
  • TNGX Strong Buy
  • Analyst Count
  • PFLT 1
  • TNGX 8
  • Target Price
  • PFLT $12.50
  • TNGX $14.86
  • AVG Volume (30 Days)
  • PFLT 824.8K
  • TNGX 822.0K
  • Earning Date
  • PFLT 08-07-2024
  • TNGX 08-05-2024
  • Dividend Yield
  • PFLT 10.74%
  • TNGX N/A
  • EPS Growth
  • PFLT N/A
  • TNGX N/A
  • EPS
  • PFLT 1.54
  • TNGX N/A
  • Revenue
  • PFLT $155,774,000.00
  • TNGX $37,232,000.00
  • Revenue This Year
  • PFLT $14.65
  • TNGX N/A
  • Revenue Next Year
  • PFLT $23.17
  • TNGX $2.40
  • P/E Ratio
  • PFLT $7.42
  • TNGX N/A
  • Revenue Growth
  • PFLT 29.37
  • TNGX 49.72
  • 52 Week Low
  • PFLT $9.69
  • TNGX $2.88
  • 52 Week High
  • PFLT $12.63
  • TNGX $13.03
  • Technical
  • Relative Strength Index (RSI)
  • PFLT 40.15
  • TNGX 59.16
  • Support Level
  • PFLT $11.36
  • TNGX $9.26
  • Resistance Level
  • PFLT $12.02
  • TNGX $9.96
  • Average True Range (ATR)
  • PFLT 0.17
  • TNGX 0.66
  • MACD
  • PFLT -0.06
  • TNGX -0.00
  • Stochastic Oscillator
  • PFLT 25.86
  • TNGX 88.99

About TNGX Tango Therapeutics Inc.

Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.

Share on Social Networks: